SCHEMBL6313288

SCHEMBL6313288

CCOC(=O)c1cnn(-c2ccc(S(=O)(=O)NC)cc2Cl)c1C1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
TP53 P04637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
MAPT P10636 1/20 0.42
KEAP1 Q14145 5/20 0.41
NFE2L2 Q16236 5/20 0.41
HTT P42858 1/20 0.40
CCR1 P32246 1/20 0.39
THRB P10828 1/20 0.39
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312351 0.93 POLB (0.46) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6312981 0.90 MEN1 (0.48) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6313187 0.90 POLB (0.52) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6319809 0.87 TP53 (0.46) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6320767 0.86 KEAP1 (0.50) NPSR1MEN1KMT2ASMN1; SMN2KEAP1
SCHEMBL6314587 0.84 KMT2A (0.56) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6319259 0.82 ALDH1A1 (0.48) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6313833 0.82 ALDH1A1 (0.48) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL6312043 0.82 POLB (0.52) POLBTP53ALDH1A1NPSR1MEN1
SCHEMBL4455122 0.81 KEAP1 (0.41) TP53MEN1KMT2AKEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974813-B2 N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia WARNER-LAMBERT COMPANY (US) 2005-12-13 US disclosed
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia PFIZER INC. 2003-08-07 US disclosed
US-6492401-B1 SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE PFIZER, INC. 2002-12-10 US disclosed
EP-1056729-A1 N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA Pfizer Products Inc. (US) 2000-12-06 EP disclosed
WO-1999043663-A1 N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA PFIZER PRODUCTS INC. (US) 1999-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia NHERF1, SLC28A1, TNNI3 POLB 2803/4885TP53 4706/4885ALDH1A1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.